HRP20201530T1 - Kompozicije koje sadrže aav koji eksprimira konstrukte dvojnih antitijela i njihove primjene - Google Patents

Kompozicije koje sadrže aav koji eksprimira konstrukte dvojnih antitijela i njihove primjene Download PDF

Info

Publication number
HRP20201530T1
HRP20201530T1 HRP20201530TT HRP20201530T HRP20201530T1 HR P20201530 T1 HRP20201530 T1 HR P20201530T1 HR P20201530T T HRP20201530T T HR P20201530TT HR P20201530 T HRP20201530 T HR P20201530T HR P20201530 T1 HRP20201530 T1 HR P20201530T1
Authority
HR
Croatia
Prior art keywords
recombinant aav
expression cassette
orf
expression
recombinant
Prior art date
Application number
HRP20201530TT
Other languages
English (en)
Inventor
James M. Wilson
Anna Tretiakova
Original Assignee
The Trustees Of The University Of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of The University Of Pennsylvania filed Critical The Trustees Of The University Of Pennsylvania
Publication of HRP20201530T1 publication Critical patent/HRP20201530T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • C12N2830/205—Vector systems having a special element relevant for transcription transcription of more than one cistron bidirectional
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)

Claims (20)

1. Rekombinantni adeno-asocirani virus (AAV - recombinant adeno-associated virus) koji ima AAV kapsidu i u njemu upakiranu heterolognu nukleinsku kiselinu koja eksprimira dva funkcionalna monospecifična antitijela u stanici, gdje rekombinantni AAV sadrži: 5' AAV invertirano terminalno ponavljanje (ITR); prvu ekspresijsku kasetu koja kodira barem prvi otvoreni okvir čitanja (ORF – open reading frame) za prvi imunoglobulin pod kontrolom regulatornih kontrolnih sekvenci koje upravljaju njegovim eksprimiranjem; drugu ekspresijsku kasetu koja sadrži drugi ORF, veznik, i treći ORF pod kontrolom regulatornih kontrolnih sekvenci koje upravljaju njegovim eksprimiranjem, gdje su drugi i treći ORF za drugi i treći imunoglobulinski konstrukt; i 3'AAV ITR, pri čemu su laki lanac imunoglobulina, prvi teški lanac imunoglobulina i drugi teški lanac imunoglobulina kodirani.
2. Rekombinantni AAV prema patentnom zahtjevu 1, pri čemu rekombinantni AAV dalje eksprimira bispecifično antitijelo.
3. Rekombinantni AAV prema patentnom zahtjevu 1, pri čemu rekombinantni AAV sadrži bidirekcijski pojačivač koji je smješten između prve ekspresijske kasete i druge ekspresijske kasete.
4. Rekombinantni AAV prema patentnom zahtjevu 1, pri čemu prvi ORF kodira laki lanac imunoglobulina, drugi ORF kodira prvi teški lanac imunoglobulina i treći ORF kodira drugi teški lanac, pri čemu ekspresioni funkcionalni konstrukti antitijela imaju dva različita teška lanca sa različitim specifičnostima koji dijele laki lanac.
5. Rekombinantni AAV prema patentnom zahtjevu 1, gdje barem jedan od drugog ili trećeg ORF sadrži modificirane Fc kodirajuće sekvence.
6. Rekombinantni AAV prema patentnom zahtjevu 1, gdje veznik u drugoj kaseti sadrži veznik odabran od IRES ili F2A.
7. Rekombinantni AAV prema patentnom zahtjevu 1, gdje regulatorne kontrolne sekvence za prvu ekspresijsku kasetu i/ili drugu kasetu sadrže minimalni promoter.
8. Rekombinantni AAV prema patentnom zahtjevu 1, gdje regulatorne kontrolne sekvence za prvu ekspresijsku kasetu i/ili drugu ekspresijsku kasetu sadrže minimalni ili sintetički poliA.
9. Rekombinantni AAV prema patentnom zahtjevu 1, gdje je prva ekspresijska kaseta bicistronska i sadrži dalje ORF.
10. Rekombinantni AAV prema patentnom zahtjevu 9, gdje svaki od ORF sadrži scFv.
11. Rekombinantni AAV prema patentnom zahtjevu 1, gdje vektor sadrži bidirekcijski poliA između prve ekspresijske kasete i druge ekspresijske kasete.
12. Rekombinantni AAV prema patentnom zahtjevu 10, gdje prva ekspresijska kaseta sadrži pojačivač i minimalni promoter.
13. Rekombinantni AAV prema patentnom zahtjevu 12, gdje druga ekspresijska kaseta sadrži pojačivač i minimalni promoter.
14. Rekombinantni AAV prema patentnom zahtjevu 8, gdje prva i druga ekspresijska kaseta zajedno eksprimiraju dva Fab-a.
15. Rekombinantni AAV prema patentnom zahtjevu 1, gdje dva monospecifična antitijela imaju različite specifičnosti.
16. Rekombinantni AAV prema patentnom zahtjevu 1, gdje su dva monospecifična antitijela nezavisno odabrana od monoklonskog antitijela, imunoadhezina, Fab-a, bifunkcionalnog antitijela, i njihovih kombinacija.
17. Rekombinantni adeno-asocirani virus (AAV) koji ima AAV kapsidu i u njemu upakiranu heterolognu nukleinsku kiselinu koja eksprimira dva funkcionalna monospecifična antitijela, gdje rekombinantni AAV eksprimira prvo monoklonsko antitijelo koje ima prvu specifičnost, drugo monoklonsko antitijelo koje ima specifičnost različitu od prvog monoklonskog antitijela, i bispecifično antitijelo, i gdje rekombinantni AAV sadrži: 5' AAV invertirano terminalno ponavljanje (ITR); prvu ekspresijsku kasetu koja kodira barem prvi otvoreni okvir čitanja (ORF) za prvi imunoglobulin pod kontrolom regulatornih kontrolnih sekvenci koje upravljaju njegovim eksprimiranjem; drugu ekspresijsku kasetu koja sadrži drugi ORF, veznik, i treći ORF pod kontrolom regulatornih kontrolnih sekvenci koje upravljaju njegovim eksprimiranjem, gdje su drugi i treći ORF za drugi i treći konstrukt imunoglobulina; i 3'AAV ITR, pri čemu su laki lanac imunoglobulina, prvi teški lanac imunoglobulina i drugi teški lanac imunoglobulina kodirani.
18. Farmaceutska kompozicija koja sadrži rekombinantni AAV prema bilo kojem od patentnih zahtjeva 1 do 17 i farmaceutski prihvatljiv nosač.
19. Kompozicija za primjenu u postupku dostavljanja dva funkcionalna monospecifična antitijela subjektu, pri čemu navedena kompozicija sadrži rekombinantni AAV prema bilo kojem od patentnih zahtjeva 1 do 17.
20. Rekombinantni AAV prema patentnom zahtjevu 17, gdje prvi ORF kodira laki lanac imunoglobulina, drugi ORF kodira prvi teški lanac imunoglobulina i treći ORF kodira drugi teški lanac, pri čemu ekspresioni funkcionalni konstrukti antitijela imaju dva različita teška lanca sa različitim specifičnostima koji dijele laki lanac.
HRP20201530TT 2014-05-13 2020-09-24 Kompozicije koje sadrže aav koji eksprimira konstrukte dvojnih antitijela i njihove primjene HRP20201530T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461992649P 2014-05-13 2014-05-13
EP15792528.0A EP3142750B1 (en) 2014-05-13 2015-05-13 Compositions comprising aav expressing dual antibody constructs and uses thereof
PCT/US2015/030533 WO2015175639A1 (en) 2014-05-13 2015-05-13 Compositions comprising aav expressing dual antibody constructs and uses thereof

Publications (1)

Publication Number Publication Date
HRP20201530T1 true HRP20201530T1 (hr) 2020-12-11

Family

ID=54480597

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20201530TT HRP20201530T1 (hr) 2014-05-13 2020-09-24 Kompozicije koje sadrže aav koji eksprimira konstrukte dvojnih antitijela i njihove primjene

Country Status (27)

Country Link
US (4) US10138295B2 (hr)
EP (1) EP3142750B1 (hr)
JP (3) JP6974943B2 (hr)
KR (1) KR102550926B1 (hr)
CN (1) CN106470736B (hr)
AU (2) AU2015259188B2 (hr)
CA (1) CA2947614C (hr)
CL (1) CL2016002840A1 (hr)
CR (1) CR20160519A (hr)
DK (1) DK3142750T3 (hr)
EA (1) EA037980B1 (hr)
ES (1) ES2833230T3 (hr)
HR (1) HRP20201530T1 (hr)
HU (1) HUE050609T2 (hr)
IL (1) IL248508B2 (hr)
MA (2) MA44179B1 (hr)
MX (1) MX365658B (hr)
MY (1) MY186389A (hr)
PE (1) PE20170261A1 (hr)
PH (1) PH12016502239B1 (hr)
PL (1) PL3142750T3 (hr)
PT (1) PT3142750T (hr)
SA (1) SA516380285B1 (hr)
SG (1) SG11201609207SA (hr)
SI (1) SI3142750T1 (hr)
UA (1) UA123986C2 (hr)
WO (1) WO2015175639A1 (hr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
US10138295B2 (en) 2014-05-13 2018-11-27 The Trustees Of The University Of Pennsylvania Compositions comprising AAV expressing dual antibody constructs and uses thereof
US11535665B2 (en) 2015-05-13 2022-12-27 The Trustees Of The University Of Pennsylvania AAV-mediated expression of anti-influenza antibodies and methods of use thereof
WO2017096363A1 (en) * 2015-12-04 2017-06-08 Board Of Regents, The University Of Texas System Reporter system for detecting and targeting activated cells
IL259850B2 (en) * 2015-12-11 2023-11-01 Univ Pennsylvania Gene therapy for treating familial hypercholesterolemia
AU2017222564A1 (en) 2016-02-24 2018-09-06 Visterra, Inc. Formulations of antibody molecules to influenza virus
EP3442577A4 (en) * 2016-04-15 2020-03-25 REGENXBIO Inc. TREATMENT OF EYE DISEASES WITH FULLY HUMAN, POST-TRANSLATIONAL-MODIFIED ANTI-VEGF-FAB
SG11201808426XA (en) 2016-04-15 2018-10-30 Univ Pennsylvania Compositions for treatment of wet age-related macular degeneration
WO2017184463A1 (en) * 2016-04-17 2017-10-26 The Trustees Of The University Of Pennsylvania Compositions and methods useful for prophylaxis of organophosphates
WO2017189959A1 (en) * 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448987A4 (en) * 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR THE TREATMENT OF DISEASES
EP3448875A4 (en) * 2016-04-29 2020-04-08 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
BR112018072865A2 (pt) 2016-05-12 2019-04-30 Janssen Vaccines & Prevention B.V. promotor bidirecional potente e equilibrado
WO2017220499A1 (en) * 2016-06-20 2017-12-28 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
CN109996880A (zh) 2016-08-18 2019-07-09 加利福尼亚大学董事会 基于模块化aav递送系统的crispr-cas基因组工程
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
AU2018227440B2 (en) 2017-02-28 2024-06-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) clade f vector and uses therefor
WO2018160573A1 (en) * 2017-02-28 2018-09-07 The Trustees Of The University Of Pennsylvania Influenza vaccines based on aav vectors
KR20200035130A (ko) 2017-08-09 2020-04-01 바이오버라티브 테라퓨틱스 인크. 핵산 분자 및 이의 용도
AU2018316811B2 (en) * 2017-08-17 2023-07-13 The Trustees Of The University Of Pennsylvania Modified mRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof
AU2018392480A1 (en) 2017-12-19 2020-07-02 Akouos, Inc. AAV-mediated delivery of therapeutic antibodies to the inner ear
CN108424934A (zh) * 2018-04-16 2018-08-21 和元生物技术（上海）股份有限公司 一种慢病毒cag-cmv双启动子改造载体构建及应用
AU2019304569B2 (en) 2018-07-17 2023-07-06 Helixmith Co., Ltd Treatment of neuropathy with DNA constructs expressing IGF-1 isoforms
AU2019319984A1 (en) * 2018-08-09 2021-03-04 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
US20200148762A1 (en) * 2018-11-09 2020-05-14 Avamab Pharma Inc. Methods for regulating endogenous production of antibodies against infectious diseases
WO2020113199A1 (en) 2018-12-01 2020-06-04 International Aids Vaccine Initiative Recombinant hiv env polypeptides and their use
EP3898965A4 (en) * 2018-12-21 2022-10-12 Merck Sharp & Dohme Corp. Expression vectors for eukaryotic expression systems
WO2020160508A1 (en) 2019-01-31 2020-08-06 Oregon Health & Science University Methods for using transcription-dependent directed evolution of aav capsids
WO2020219868A1 (en) * 2019-04-24 2020-10-29 Regenxbio Inc. Fully-human post-translationally modified antibody therapeutics
US20210079068A1 (en) * 2019-09-17 2021-03-18 Auburn University Antibody gene therapy for treatment and prevention of infection by rabies lyssavirus
KR20220113749A (ko) * 2019-12-11 2022-08-16 비스테라, 인크. 인플루엔자를 치료하고 예방하는 조성물 및 방법
WO2022107090A1 (en) * 2020-11-23 2022-05-27 Novartis Ag Expression technology for antibody constructs
BR112023015303A2 (pt) 2021-02-01 2023-11-14 Regenxbio Inc Método para tratar doença cln2 devido a deficiência de tpp1 em um sujeito
AU2022217778A1 (en) * 2021-02-02 2023-08-31 Allen Institute Artificial expression constructs for modulating gene expression in gabaergic neurons and astrocytes
WO2024125530A1 (zh) * 2022-12-12 2024-06-20 苏州荷光科汇生物科技有限公司 一种感染视网膜的aav载体、阿达木单抗及其应用

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US6268213B1 (en) 1992-06-03 2001-07-31 Richard Jude Samulski Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
US5869305A (en) 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
CA2287478C (en) 1997-04-14 2007-06-19 Richard J. Samulski Methods for increasing the efficiency of recombinant aav product
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
US5891994A (en) 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
GB9720585D0 (en) 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
CZ121599A3 (cs) * 1998-04-09 1999-10-13 Aventis Pharma Deutschland Gmbh Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu
US6146874A (en) 1998-05-27 2000-11-14 University Of Florida Method of preparing recombinant adeno-associated virus compositions
WO2000028004A1 (en) 1998-11-10 2000-05-18 The University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
CA2379166C (en) 1999-08-09 2013-03-26 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs
US6780639B1 (en) * 1999-08-24 2004-08-24 Universite Libre De Bruxelles Antibiotic inducible/repressible genetic construct for gene therapy or gene immunization
DZ3286A1 (fr) 2000-01-31 2001-08-02 Smithkline Beecham Biologicals Nouvelle utilisation
ES2505700T3 (es) 2000-06-01 2014-10-10 University Of North Carolina At Chapel Hill Vectores de parvovirus duplicados
AU6814901A (en) 2000-06-01 2001-12-11 Univ North Carolina Methods and compounds for controlled release of recombinant parvovirus vectors
NZ578982A (en) 2001-11-13 2011-03-31 Univ Pennsylvania A method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
ES2717377T3 (es) 2001-12-17 2019-06-20 Univ Pennsylvania Secuencias de serotipo 8 de virus adeno-asociado (AAV), vectores que las contienen y usos de las mismas
US20070015238A1 (en) 2002-06-05 2007-01-18 Snyder Richard O Production of pseudotyped recombinant AAV virions
CN101537180B (zh) * 2002-07-18 2016-02-10 莫鲁斯有限公司 抗体混合物的重组生产
DE602004021095D1 (de) 2003-01-21 2009-06-25 Chugai Pharmaceutical Co Ltd Verfahren zum screening der leichten kette eines antikörpers
EP2434420A3 (en) 2003-08-01 2012-07-25 Dna Twopointo Inc. Systems and methods for biopolymer engineering
US8005620B2 (en) 2003-08-01 2011-08-23 Dna Twopointo Inc. Systems and methods for biopolymer engineering
CN102199626B (zh) 2003-09-30 2015-06-24 宾夕法尼亚大学托管会 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
US20060246079A1 (en) 2003-11-14 2006-11-02 Morrow Phillip R Neutralizing human antibodies to anthrax toxin
CA2564039A1 (en) * 2004-05-10 2005-11-17 Basf Plant Science Gmbh Methods for assembling multiple expression constructs
EP1765846A4 (en) 2004-07-13 2010-02-17 Cell Genesys Inc AAV VECTOR COMPOSITIONS AND ITS USE IN PROCESSES FOR INCREASING IMMUNOGLOBULIN EXPRESSION
CN117363655A (zh) 2005-04-07 2024-01-09 宾夕法尼亚大学托管会 增强腺相关病毒载体功能的方法
EP2007795B1 (en) 2006-03-30 2016-11-16 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid proteins
US20070292922A1 (en) 2006-03-31 2007-12-20 Cell Genesys, Inc. Regulated expression of recombinant proteins from adeno-associated viral vectors
WO2007127264A2 (en) 2006-04-28 2007-11-08 The Trustees Of The University Of Pennsylvania Scalable production method for aav
CA2678451A1 (en) 2007-02-20 2008-08-28 Robert A. Horlick Somatic hypermutation systems
CA2684534C (en) 2007-04-17 2017-04-04 National Research Council Of Canada Constructs for enhancement of gene expression in muscle
WO2008156763A2 (en) 2007-06-15 2008-12-24 The Board Of Trustees Of The Leland Stanford Junior University Human neutralizing monoclonal antibodies to h5n1 influenza a virus
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
EP2313435A4 (en) 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
RU2553325C2 (ru) 2008-07-25 2015-06-10 Институт Фо Ресёч Ин Биомедицин Нейтрализующие антитела против вируса гриппа а и их использование
WO2010084197A1 (en) 2009-01-26 2010-07-29 Genmab A/S Methods for producing mixtures of antibodies
HRP20221471T1 (hr) 2009-03-25 2023-02-03 Genentech, Inc. Protutijela anti-fgfr3 i postupci za njihovu uporabu
US20120052064A1 (en) 2009-04-17 2012-03-01 Yuuki Ito Anti-hgf antibody combinational cancer therapies
EP2430046B1 (en) 2009-05-11 2022-09-28 Janssen Vaccines & Prevention B.V. Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
IT1395961B1 (it) 2009-06-01 2012-11-02 Pomona Biotechnologies Llc Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv)
JP5745511B2 (ja) 2009-06-25 2015-07-08 メディミューン，エルエルシー ブタインフルエンザヘマグルチニン変異体
CN101649328A (zh) * 2009-09-09 2010-02-17 陕西师范大学 表达多个外源基因的Ad5 D24条件复制型腺病毒载体及其构建方法和应用
US8598331B2 (en) 2009-09-28 2013-12-03 The University Of British Columbia CLDN5 mini-promoters
EP2501817B2 (en) 2010-02-08 2021-04-21 Regeneron Pharmaceuticals, Inc. Common light chain mouse
US20130017130A1 (en) 2010-03-30 2013-01-17 Haubert Thomas D Buffy coat separator float systems and methods
RU2012153241A (ru) 2010-05-11 2014-06-20 Авео Фармасьютикалз, Инк. Антитела к fgfr2
EP2582722A4 (en) 2010-06-19 2013-12-18 Sloan Kettering Inst Cancer ANTIBODIES AGAINST GD2
CN105884898B (zh) 2010-08-13 2022-10-11 罗切格利卡特公司 抗成纤维细胞激活蛋白抗体及使用方法
AU2011290480B2 (en) * 2010-08-16 2015-07-30 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
US8865881B2 (en) 2011-02-22 2014-10-21 California Institute Of Technology Delivery of proteins using adeno-associated virus (AAV) vectors
EP2500434A1 (en) * 2011-03-12 2012-09-19 Association Institut de Myologie Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
SG185832A1 (en) 2011-05-10 2012-12-28 Agency Science Tech & Res Fgfr1 antibodies and treatment of cancer
CA2828890A1 (en) 2011-04-07 2012-10-11 Genentech, Inc. Anti-fgfr4 antibodies and methods of use
EP3699286A1 (en) 2011-04-20 2020-08-26 The Trustees of the University of Pennsylvania Regimens and compositions for aav-mediated passive immunization of airborne pathogens
WO2012145759A2 (en) 2011-04-21 2012-10-26 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Methods of protein production and compositions thereof
EP2748394B1 (en) 2011-09-29 2019-01-09 Avery Dennison Corporation Anti-theft security device to increase marketing opportunities
TW201326209A (zh) 2011-09-30 2013-07-01 Chugai Pharmaceutical Co Ltd 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
US9127056B2 (en) 2011-10-17 2015-09-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monospecific and bispecific human monoclonal antibodies targeting insulin-like growth factor II (IGF-II)
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
WO2013155222A2 (en) 2012-04-10 2013-10-17 The Regents Of The University Of California Brain-specific enhancers for cell-based therapy
WO2013163427A1 (en) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
ES2846623T3 (es) 2012-05-22 2021-07-28 Bristol Myers Squibb Co Anticuerpos biespecíficos y métodos de uso de los mismos
EP2880053B8 (en) * 2012-08-01 2020-04-15 Ikaika Therapeutics, LLC Mitigating tissue damage and fibrosis via anti-ltbp4 antibody
US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
WO2015142661A1 (en) 2014-03-15 2015-09-24 Novartis Ag Regulatable chimeric antigen receptor
US10138295B2 (en) 2014-05-13 2018-11-27 The Trustees Of The University Of Pennsylvania Compositions comprising AAV expressing dual antibody constructs and uses thereof

Also Published As

Publication number Publication date
PH12016502239A1 (en) 2017-01-09
IL248508B2 (en) 2023-02-01
KR102550926B1 (ko) 2023-07-05
AU2021204630A1 (en) 2021-07-29
WO2015175639A1 (en) 2015-11-19
PT3142750T (pt) 2020-09-22
US20190322725A1 (en) 2019-10-24
US20200216520A1 (en) 2020-07-09
ES2833230T3 (es) 2021-06-14
SG11201609207SA (en) 2016-12-29
JP2020141697A (ja) 2020-09-10
CA2947614C (en) 2023-10-03
MY186389A (en) 2021-07-22
MX2016014813A (es) 2017-03-10
CN106470736A (zh) 2017-03-01
US20190031740A1 (en) 2019-01-31
MA44179B1 (fr) 2020-10-28
US10138295B2 (en) 2018-11-27
DK3142750T3 (da) 2020-09-14
CR20160519A (es) 2017-01-27
IL248508B (en) 2022-10-01
NZ725622A (en) 2023-10-27
US10385119B2 (en) 2019-08-20
JP7229298B2 (ja) 2023-02-27
CA2947614A1 (en) 2015-11-19
SA516380285B1 (ar) 2020-04-30
HUE050609T2 (hu) 2021-01-28
JP2017515482A (ja) 2017-06-15
EP3142750B1 (en) 2020-07-01
CL2016002840A1 (es) 2017-05-05
MX365658B (es) 2019-06-10
BR112016026092A2 (pt) 2017-12-12
AU2015259188B2 (en) 2021-07-29
EP3142750A4 (en) 2017-10-18
EP3142750A1 (en) 2017-03-22
US10975140B2 (en) 2021-04-13
UA123986C2 (uk) 2021-07-07
JP2021121217A (ja) 2021-08-26
MA44179A1 (fr) 2019-07-31
PE20170261A1 (es) 2017-04-12
AU2015259188A1 (en) 2016-11-10
CN106470736B (zh) 2021-05-28
MA39437A1 (fr) 2018-01-31
AU2021204630B2 (en) 2024-03-14
PH12016502239B1 (en) 2017-01-09
JP6974943B2 (ja) 2021-12-01
KR20170002445A (ko) 2017-01-06
IL248508A0 (en) 2016-12-29
EA201692293A1 (ru) 2017-04-28
US20170081392A1 (en) 2017-03-23
EA037980B1 (ru) 2021-06-18
PL3142750T3 (pl) 2021-03-08
SI3142750T1 (sl) 2020-11-30
US10647758B2 (en) 2020-05-12

Similar Documents

Publication Publication Date Title
HRP20201530T1 (hr) Kompozicije koje sadrže aav koji eksprimira konstrukte dvojnih antitijela i njihove primjene
JP2017515482A5 (hr)
HRP20202024T1 (hr) Cd3-vežuća domena
JP2018502561A5 (hr)
HRP20190706T1 (hr) Miševi koji izražavaju ograničeni repertoar lakog lanca imunoglobulina
HRP20240774T1 (hr) Anti-il-33 antitijela i njihove upotrebe
JP2012116856A5 (hr)
JP2018121657A5 (hr)
HRP20200164T1 (hr) Bispecifična protutijela koja se vežu na cd38 i cd3
Goodchild et al. A humanised murine monoclonal antibody with broad serogroup specificity protects mice from challenge with Venezuelan equine encephalitis virus
HRP20240576T1 (hr) Cd19 specifični kimerni antigenski receptor i njegova upotreba
HRP20240719T1 (hr) Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba
HRP20241502T1 (hr) Bispecifična tetravalentna protutijela i postupci za njihovu proizvodnju i uporabu
JP2019520063A5 (hr)
HRP20220799T1 (hr) Klaudin-18-2-specifični imunoreceptori i stanični epitopi t
JP2014158485A5 (hr)
JP2019513370A5 (hr)
EP4286415A3 (en) Humanized antigen-binding domains against cd19 and methods of use
HRP20191233T1 (hr) Antitijela lakog lanca modificirana histidinom i genetski modificirane nehumane životinje za dobivanje istih
JP2017114866A5 (hr)
AR108066A1 (es) Receptores quiméricos para cll-1 y métodos de uso de los mismos
JP2014534207A5 (hr)
JP2017163973A5 (hr)
JP2017504578A5 (hr)
JP2017529067A5 (hr)